The University of Chicago
Hyde Park, Illinois, 60637, United States
Location status: Recruiting
Location contact
Leila Yazdanbakhsh
CONTACT
Valluvan Jeevanandam
PRINCIPAL_INVESTIGATOR
Valluvan Jeevanandam, MD
CONTACT
Recruiting
NCT Number: NCT06747806
Biobank Cardiac Surgery
Treatment strategies for cardiac surgery patients have been evolving significantly for the last decade. While clinical outcomes have been improving, there are still significant areas unexplored in these patients. Cardiac surgery, or cardiovascular surgery, is surgery on the heart or great vessels performed by cardiac surgeons. It is often used to treat complications of ischemic heart disease (for example, with coronary artery bypass grafting); to correct congenital heart disease; or to treat valvular heart disease from various causes, including endocarditis, rheumatic heart disease, and atherosclerosis.
Biobanking is a fundamental process required in the better understanding of human diseases together with their underlying mechanisms. Biobanking refers to the process by which samples of bodily fluid or tissue are collected for research use to improve the understanding of health and disease. For this study, the investigator's objective is to acquire elucidation in disease etiology, translation, and advancing public health by evaluating blood and tissue results of those with cardiac disease undergoing cardiac surgery.
Recruiting
Interested in participating?
Request InfoKey information
Conditions
Sex eligibility
All sexes
Study type
Observational
Primary location
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- All patients who undergo cardiac surgery at Advocate Children's Hospital (ACH)& University of Chicago Medical Center (UCMC) by the ACH & UC Cardiothoracic Surgery Research team who are pediatric neonates and up.
- Patients will only be English speaking.
Exclusion criteria
- Vulnerable Subjects/Subject Capacity to provide consent
Treatment and study plan
Cardiac Surgery and Procedures
ProcedureTo assess blood and tissue biomarkers of patients undergoing cardiac surgery
Primary outcomes
-
Concentration of the elucidation in disease etiology from evaluating blood and tissue results
Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months
To acquire elucidation in disease etiology health by evaluating blood and tissue results of those with cardiac disease undergoing cardiac surgery.
-
Concentration of the elucidation in disease translation from evaluating blood and tissue results
Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months
To acquire elucidation in disease translational health by evaluating blood and tissue results of those with cardiac disease undergoing cardiac surgery.
-
Concentration of the elucidation in advancing public health by evaluating blood and tissue results
Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months
To acquire elucidation in advancing public health by evaluating blood and tissue results of those with cardiac disease undergoing cardiac surgery.
Study contacts
Contact information is provided by the study sponsor or research team.
Leila Yazdanbakhsh
CONTACT
Valluvan Jeevanandam, MD
CONTACT
Sponsors and collaborators
Lead sponsor
University of Chicago
Other
Registry information
Official study title
Biobank of Blood and Tissue Samples From Patients Undergoing Cardiac Surgery
Important dates
- Study start
- 2023
- Primary completion
- 2028
- Study completion
- 2028
- First posted
- Dec 24, 2024
- Registry last updated
- Dec 19, 2025
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Recruiting
Fibrotic Disease Activity in Cardiopulmonary Disorders Using 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) PET/CT Imaging
NCT07613099
Acute Lung Injury, Allogeneic Stem Cell Transplantation
Bethesda, Maryland, United States
View Trial Details
Recruiting
Medtronic SYMBIOSIS Post-Market Registry for Patients Undergoing Cardiac Surgery
NCT04241328
Cardiovascular Diseases
Vienna, Austria
View Trial Details
Recruiting
A Study to See if Lepodisiran Can Reduce Plaque in Coronary Arteries of Adults With Elevated Lp(a) Who Have Had Heart Events or Are at High Risk
NCT07613294
Arterial Occlusive Diseases, Arteriosclerosis
La Jolla, California, United States
View Trial Details
Recruiting
The Effect of Dapagliflozin on Exercise and Cardiac Functional Status of Patients After Fontan Procedure
NCT07482943
Cardiovascular Abnormalities, Cardiovascular Diseases
Hong Kong
View Trial Details